Limits...
In Vivo and Impression Cytology Study on the Effect of Compatible Solutes Eye Drops on the Ocular Surface Epithelial Cell Quality in Dry Eye Patients.

Lanzini M, Curcio C, Colabelli-Gisoldi RA, Mastropasqua A, Calienno R, Agnifili L, Nubile M, Mastropasqua L - Mediators Inflamm. (2015)

Bottom Line: No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups.A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment.Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine and Ageing Sciences, Ophthalmology Clinic, University "G. d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.

ABSTRACT
The aim of this study is to investigate in vivo and ex vivo ocular surface alterations induced by dry eye disease and modification after osmoprotective therapy. Forty-eight eyes of 24 patients suffering from dry eye have been recruited. All patients received Optive (compatible solutes) eye drops in one randomly selected eye and Hylogel (sodium hyaluronate 0,2%) in the other. Follow-up included a baseline visit and further examination 30-, 60-, and 90-day intervals (which comprises clinical evaluation, in vivo confocal microscopy-IVCM-of the ocular surface, and conjunctival impression cytology). No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups. IVCM showed in all patients an improvement of ocular surface epithelial morphology and signs of inflammation (oedema and keratocyte activation). However, these modifications were more evident in patients treated with Optive therapy. A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment. Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

No MeSH data available.


Related in: MedlinePlus

IVCM images of ocular surface inflammation in dry eye. (a) Numerous activated keratocytes in corneal anterior stroma. (b) High number of dendritic cells in corneal subepithelium. (c–f) Reduction of inflammation signs in corneal stroma and subepithelial layer, more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499618&req=5

fig2: IVCM images of ocular surface inflammation in dry eye. (a) Numerous activated keratocytes in corneal anterior stroma. (b) High number of dendritic cells in corneal subepithelium. (c–f) Reduction of inflammation signs in corneal stroma and subepithelial layer, more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).

Mentions: Stromal reflectivity showed a significant decrease both in Optive group (p = 0,0009) and in Hylogel group (p = 0,0400) at the end of follow-up period. Moreover, a significant difference was observed at 90 days comparing the two treatment groups (p = 0,0009) (Figure 2).


In Vivo and Impression Cytology Study on the Effect of Compatible Solutes Eye Drops on the Ocular Surface Epithelial Cell Quality in Dry Eye Patients.

Lanzini M, Curcio C, Colabelli-Gisoldi RA, Mastropasqua A, Calienno R, Agnifili L, Nubile M, Mastropasqua L - Mediators Inflamm. (2015)

IVCM images of ocular surface inflammation in dry eye. (a) Numerous activated keratocytes in corneal anterior stroma. (b) High number of dendritic cells in corneal subepithelium. (c–f) Reduction of inflammation signs in corneal stroma and subepithelial layer, more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499618&req=5

fig2: IVCM images of ocular surface inflammation in dry eye. (a) Numerous activated keratocytes in corneal anterior stroma. (b) High number of dendritic cells in corneal subepithelium. (c–f) Reduction of inflammation signs in corneal stroma and subepithelial layer, more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).
Mentions: Stromal reflectivity showed a significant decrease both in Optive group (p = 0,0009) and in Hylogel group (p = 0,0400) at the end of follow-up period. Moreover, a significant difference was observed at 90 days comparing the two treatment groups (p = 0,0009) (Figure 2).

Bottom Line: No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups.A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment.Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine and Ageing Sciences, Ophthalmology Clinic, University "G. d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.

ABSTRACT
The aim of this study is to investigate in vivo and ex vivo ocular surface alterations induced by dry eye disease and modification after osmoprotective therapy. Forty-eight eyes of 24 patients suffering from dry eye have been recruited. All patients received Optive (compatible solutes) eye drops in one randomly selected eye and Hylogel (sodium hyaluronate 0,2%) in the other. Follow-up included a baseline visit and further examination 30-, 60-, and 90-day intervals (which comprises clinical evaluation, in vivo confocal microscopy-IVCM-of the ocular surface, and conjunctival impression cytology). No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups. IVCM showed in all patients an improvement of ocular surface epithelial morphology and signs of inflammation (oedema and keratocyte activation). However, these modifications were more evident in patients treated with Optive therapy. A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment. Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

No MeSH data available.


Related in: MedlinePlus